Several other equities research analysts have also recently weighed in on the company. HC Wainwright dropped their target price on BioNTech from $283.00 to $272.00 and set a buy rating for the company in a report on Wednesday, August 10th. The Goldman Sachs Group dropped their price objective on BioNTech from $200.00 to $177.00 and set a neutral rating for the company in a report on Tuesday, November 8th. UBS Group set a $168.00 price objective on BioNTech in a report on Tuesday, November 15th. Cowen started coverage on BioNTech in a report on Wednesday, August 17th. They issued a market perform rating and a $177.00 price objective for the company. Finally, Morgan Stanley increased their price objective on BioNTech from $194.00 to $203.00 and gave the stock an equal weight rating in a report on Tuesday, November 8th. Seven research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, BioNTech presently has an average rating of Hold and a consensus target price of $217.15.
BioNTech Price Performance
Shares of BioNTech stock opened at $156.23 on Monday. The company has a current ratio of 5.37, a quick ratio of 5.30 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $37.91 billion, a PE ratio of 3.53 and a beta of 0.12. The business’s 50-day moving average price is $142.25 and its 200-day moving average price is $149.59. BioNTech has a 12 month low of $117.08 and a 12 month high of $374.58.
Hedge Funds Weigh In On BioNTech
Several institutional investors and hedge funds have recently bought and sold shares of the stock. International Biotechnology Trust PLC purchased a new position in shares of BioNTech in the second quarter valued at about $26,000. Eagle Bay Advisors LLC purchased a new position in shares of BioNTech in the second quarter valued at about $33,000. Huntington National Bank purchased a new position in shares of BioNTech in the third quarter valued at about $34,000. Heritage Wealth Management LLC purchased a new position in shares of BioNTech in the second quarter valued at about $36,000. Finally, Activest Wealth Management increased its holdings in shares of BioNTech by 39,000.0% in the third quarter. Activest Wealth Management now owns 391 shares of the company’s stock worth $53,000 after purchasing an additional 390 shares during the last quarter. 13.77% of the stock is currently owned by hedge funds and other institutional investors.
BioNTech Company Profile
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer.
- Get a free copy of the StockNews.com research report on BioNTech (BNTX)
- Microsoft Shares: Is it Time to Back Up the Truck?
- Is the 60/40 Portfolio Mix Still in Vogue?
- Institutional Support for Analog Devices Remains High
- Three CBD Stocks to Dominate a Budding Industry
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
Receive News & Ratings for BioNTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNTech and related companies with MarketBeat.com's FREE daily email newsletter.